ganciclovir sodium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ganciclovir sodium: clinical details
Prescribing considerations
- Confirm the licensed indication and involve an appropriate CMV, infection, transplant, oncology or paediatric specialist.
- Review baseline renal function, full blood count, platelets, pregnancy potential and interacting medicines.
- Renal impairment substantially increases exposure and haematological toxicity.
- Exercise particular caution in children because of potential reproductive and long-term carcinogenic toxicity.
- Use appropriate hazardous-medicine precautions during preparation and disposal.
Contraindications and cautions
- Hypersensitivity to ganciclovir, valganciclovir or a formulation excipient.
- Breastfeeding.
- Do not initiate when blood counts are below the product-specific SmPC thresholds.
Monitoring
- Full blood count with differential and platelets; increase surveillance in renal impairment, neonates, infants or patients with prior cytopenia.
- Serum creatinine or estimated creatinine clearance.
- Clinical and virological response; consider resistance when response remains poor or viral shedding persists.
- Infusion site and neurological, renal and haematological toxicity.
Clinical pharmacology
Ganciclovir is preferentially phosphorylated in CMV-infected cells, then inhibits viral DNA polymerase and DNA elongation. It undergoes little metabolism and is predominantly excreted unchanged by the kidneys; clearance closely follows renal function.
Formulation and product differences
- Both selected products are single-use powders requiring reconstitution and further dilution for intravenous infusion.
- Prepared solutions are alkaline and must not be administered intramuscularly or subcutaneously.
ganciclovir sodium preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 500 mg
ganciclovir sodium interactions
Review all prescribed, over-the-counter and specialist medicines because kidney and bone-marrow toxicity can be additive.
Imipenem with cilastatin
Concurrent use has been associated with seizures and is generally avoided unless the expected benefit outweighs the risk.
Probenecid
May reduce ganciclovir clearance and increase exposure, requiring closer toxicity monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.